Get the Stockscreener App
2.00
2.04%
0.04
Opus Genetics Inc stock is traded at $2.00, with a volume of 56,528.
It is up +2.04% in the last 24 hours and up +44.93% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$1.96
Open:
$1.99
24h Volume:
56,528
Relative Volume:
0.20
Market Cap:
$119.82M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-1.8349
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
-0.99%
1M Performance:
+44.93%
6M Performance:
+182.29%
1Y Performance:
+0.00%
1-Day Range:
$1.97
$2.02
1-Week Range:
$1.85
$2.1596
52-Week Range:
$0.65
$2.1596
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
2.00 | 117.42M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.45 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.17 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
Opus Genetics Inc Stock (IRD) Latest News
Is Opus Genetics Inc. stock a safe haven assetDividend Hike & Growth Oriented Trading Recommendations - newser.com
Is Opus Genetics Inc. (R3X1) stock at risk of policy regulationMarket Activity Report & Free Fast Gain Swing Trade Alerts - newser.com
Opus Genetics (NASDAQ:IRD) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
How big funds are accumulating Opus Genetics Inc. (R3X1) stockJuly 2025 Sentiment & Low Drawdown Momentum Trade Ideas - newser.com
Can trapped investors hope for a rebound in Opus Genetics Inc.Earnings Performance Report & Risk Managed Investment Entry Signals - newser.com
What analysts say about Opus Genetics Inc R3X1 stockCapital Gains Strategies & Exceptional Profit Portfolio - earlytimes.in
Combining machine learning predictions for Opus Genetics Inc.Analyst Upgrade & Risk Adjusted Buy/Sell Alerts - newser.com
What data driven models say about Opus Genetics Inc.’s futureEarnings Overview Report & Stepwise Entry/Exit Trade Alerts - newser.com
Opus Genetics reports positive pediatric data from LCA5 gene therapy study - Eyes On Eyecare
Opus Genetics, Inc. (NASDAQ:IRD) Sees Large Increase in Short Interest - MarketBeat
How Opus Genetics Inc. (R3X1) stock performs in volatility spikesJuly 2025 Final Week & Weekly Setup with High ROI Potential - newser.com
Using R and stats models for Opus Genetics Inc. forecastingQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Opus Genetics Inc. stock daily chart insightsQuarterly Profit Review & Reliable Breakout Forecasts - newser.com
Opus Genetics (NASDAQ:IRD) Trading Up 4.4%Should You Buy? - MarketBeat
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewswire
Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice - sharewise.com
Craig-Hallum Maintains Opus Genetics(IRD.US) With Buy Rating - 富途牛牛
What drives Opus Genetics Inc stock pricePrice Gap Trading Strategies & Capitalize On Fast Trends - earlytimes.in
H.C. Wainwright reiterates Buy rating on Opus Genetics stock, citing positive data - Investing.com Canada
Why pension funds invest in Opus Genetics Inc. (R3X1) stockWeekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
H.C. Wainwright Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Can Opus Genetics Inc. stock maintain operating marginsJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Opus Genetics Reports Positive Pediatric Data from - GlobeNewswire
Magnum Opus: Street drinks in LCA5 gene therapy phase I/II data - BioWorld MedTech
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) - GlobeNewswire
Opus Genetics Shares Encouraging Data From Inherited Retinal Degeneration Study - Nasdaq
Opus Genetics reports positive data from LCA5 gene therapy trial By Investing.com - Investing.com Australia
Opus Genetics reports positive data from LCA5 gene therapy trial - Investing.com India
Opus Genetics reports positive pediatric data from OPGx-LCA5 phase 1/2 trial in Leber congenital amaurosis type 5 (LCA5) - MarketScreener
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opus Genetics Inc Stock (IRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Nov 21 '24 |
Buy |
0.98 |
10,000 |
9,834 |
342,800 |
| Magrath George | Chief Executive Officer |
Nov 15 '24 |
Buy |
1.01 |
90,294 |
91,215 |
483,244 |
| Magrath George | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.02 |
9,706 |
9,943 |
492,950 |
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):